Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection

Gene Therapy

Volumn 6, Issue 6, 1999, Pages 1054-1063

  Brand, K ^a   Klocke, R ^b   Possling A ^a   Paul, D ^b   Strauss, M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Adenovirus; Apoptosis; G2 M arrest

Indexed keywords

MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; KNOCKOUT MOUSE; LIVER CELL; METAPHASE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; ULTRAVIOLET RADIATION; VIRUS INFECTION; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; G2 PHASE; GENES, P53; HUMANS; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; ULTRAVIOLET RAYS; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA;

EID: 0032982299     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300914     Document Type: Article

References (40)

1. Amalfitano A et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
2. Nevins JR. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981; 26: 213-220.
3. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
4. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adeno-viruses with large deletions generated by CRE-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
5. Li Q et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-409.
6. Lieber A et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-8807.
7. Nielsen LL et al. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenogaft models. Hum Gene Ther 1998; 9: 681-694.
8. Teodoro JG, Branton PE. Regulation of apoptosis by viral gene products. J Virol 1997; 71: 1739-1746.
9. Heyman RA et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci USA 1989; 86: 2698-2702.
10. Macri P, Gordon JW. Delayed morbidity and mortality of albumin/SV40 T-antigen transgenic mice after insertion of an alpha-fetoprotein/herpes virus thymidine kinase transgene and treatment with ganciclovir. Hum Gene Ther 1994 5: 175-182.
11. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
12. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10: 2438-2451.
13. Bressac B et al. Abnormal structure and expression of p53 gene in hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 1973-1976.
14. Hosono S et al. Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. Oncogene 1991; 6: 237-243.
15. Noble JR, Willetts KE, Mercer WE, Reddel RR. Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res 1992; 203: 297-304.
16. Löser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFκB. J Virol 1998; 72: 180-190.
17. Allen RT, Cluck, MW, Agrawal DK. Mechanisms controling cellular suicide: role of Bcl-2 and caspases. Cell Mol Life Sci 1998; 54: 427-445.
18. Clesham GJ et al. High adenoviral loads stimulate NF kappaB-dependent gene expression in human vascular smooth muscle cells. Gene Therapy 1998; 5: 174-180.
19. Lin KI et al. Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. J Cell Biol 1995; 131: 1149-1161.
20. Marianneau P et al. Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J Virol 1997; 71: 3244-3249.
21. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20.
22. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol 1997; 71: 398-404.
23. Downward J. Ras signaling and apoptosis. Curr Opin Genet Dev 1998; 8: 49-54.
24. Tollefson AE et al. The adenovirus death protein (E3-116K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306.
25. Marcellus RC et al. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. J Virol 1996; 70: 6207-6215.
26. Klessig DF, Brough DE, Cleghon V. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol Cell Biol 1984; 4: 1354-1362.
27. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70: 7030-7038.
28. Spergel JM, Chen Kiang S. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc Natl Acad Sci USA 1991; 88: 6472-6476.
29. He J et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2-phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995; 69: 6705-6711.
30. Jault FM et al. Cytomegalovirus infection induces high levels of cyclins, phosphorylated RB, and p53, leading to cell cycle arrest. J Virol 1995; 69: 6697-6704.
31. Wersto RP et al. Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J Virol 1998; 72: 9491-9502.
32. Teramoto S et al. Effect of adenoviral vector infection on cell proliferation in cultured primary human airway epithelial cells. Hum Gene Ther 1995; 6: 1045-1053.
33. Donehower LA et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356: 215-221.
34. Brand K et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997; 4: 9-16.
35. Zhang WW et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1993;1: 5-13.
36. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626-630.
37. Dion LD, Fang J, Garver RI Jr. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Meth 1996; 56: 99-107.
38. Sandig V et al. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Therapy 1996; 3: 1002-1009.
39. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967; 26: 365-369.
40. Cotten M et al. Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Virology 1994; 205: 254-261.